Santhera and Genzyme sign option and licence agreement

Published: 11-Oct-2004

Swiss drug discovery and development company Santhera Pharmaceuticals has granted a non-exclusive licence to its proprietary cellular screening system to Genzyme Corporation for the discovery of novel therapies for a variety of muscle diseases including Duchenne Muscular Dystrophy.


Swiss drug discovery and development company Santhera Pharmaceuticals has granted a non-exclusive licence to its proprietary cellular screening system to Genzyme Corporation for the discovery of novel therapies for a variety of muscle diseases including Duchenne Muscular Dystrophy.

Genzyme also has the option to obtain an exclusive worldwide license to develop and commercialise a subset of Santhera's novel small molecule compounds for the treatment of Duchenne Muscular Dystrophy and related diseases.

Under the terms of the agreement, Santhera will receive a technology license fee. Financial details of the transaction were not disclosed.

  

You may also like